耐药性泌乳素型垂体腺瘤的多巴胺受体激动药的治疗机制、方法及进展

Abstract
Figure/Table
References
Related Citation (6)

[1]	Gerald R,Nathalie S,Florence F, et al.Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas:a French multicenter experience[J] .Clin Endocrinol Metab, 2010,95(10):4592-4599.
[2]	Bianchi A,Valentini F,Luorio R,et al.Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs:a retrospective analysis of clinical practice and outcomes[J] .Exp Clin Cancer Res, 2013,32:40.
[3]	Daniel C R,Maria F.Somatostatin receptor ligands and resistance to treatment in pituitary adenomas[J] .J Mol Endocrinol,2014,52:223-240.
[4]	Molitch M E.Pharmacologic resistance in prolactinomapatients[J] . Pituitary,2005,8:43-52.
[5]	Mark E. Molitch：management of medically refractory prolactinoma[J] .Neurooncol, 2014,117:421-428.
[6]	Juan J A，Sang R C，Won J, et al.Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells[J] .Molecular and Cellular Endocrinology,2003, 206: 49-62.
[7]	Picetti R，Saiardi A，Abdel S T, et al.Dopamine D2 receptors in signal transduction and behavior[J] . Crit Rev Neurobiol,1997, 11:121-142.
[8]	Missale C，Nash S R，Robinson S W, et al.Dopamine receptors: from structure to function[J] .Physiol Rev,1998, 78:189-225.
[9]	Gillam M P, Molitch M P, Lombardi G, et al. Advances in the treatment of prolactinomas[J] . Endocr Rev,2012, 27:485–534.
[10]	Melmed S, Casaneuva F F, Hoffman A R, et al.Diagnosis and treatment of hyperprolactinemia. an endocrine society clinical practice guideline[J] . Clin Endocrinol Metab, 2011,96:273-288.
[11]	Roth B L.Drugs and valvular heart disease[J] . Engl J Med,2007, 356:6-9.
[12]	Antonini A, Poewe W.Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease[J] . Lancet Neurol,2006, 6:826-829.
[13]	Trifiro’ G, Mokhles M M, Dieleman J P,et al.Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson’s disease and hyperprolactinemia[J] .A multi-country, 2012, 35:159-171.
[14]	Oh M C, Aghi M K .Dopamine agonist-resistant prolactinomas[J] .Neurosurg,2011, 114:1369-1379.
[15]	Colao A, Ferone D, Marzullo P, et al.Effect of different dopaminergic agents in the treatment of acromegaly[J] . Clin Endocrinol,1997, 82: 518-523 .
[16]	Cozzi R, Attanasio R, Lodrini S, et al.Cabergoline addition to depot somatostatin analogues in resistant acromegalicpatients:efficacy and lack of predictive value of prolactin status[J] . Clin Endocrinol, 2004, 61: 209-215.
[17]	Gatta B, Hau D, Catargi B, et al.Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalicpatients[J] . Clin Endocrinol,2005, 63:477-478.
[18]	DiSarno A, Landi M L, Cappabianca P,et al.Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy[J] . Clin Endocrinol Metab,2001, 86:5256-5261.
[19]	Molitch M E.Pharmacologic resistance in prolactinomapatients[J] . Pituitary,2005,8:43-52.
[20]	Pascal V V, Weryha G, Bose M, et al.Hyperprolactinemic amenorrhea: treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study[J] . Presse Med,1995, 24:754-757.
[21]	Maurer R A.Estradiol regulates the transcription of the prolactin gene[J] . Biol Chem,1982, 257:2133-2136.
[22]	Lloyd G M, Meares J D, Jacobi J.Effects of oestrogen and bromocriptine on in vivo secretion and mitosis in prolactin cells[J] .Nature,1975, 255:497-498.
[23]	Pasqualini C, Bojda F, Kerdelhue’ B.Direct effect of estradiol on the number of dopamine receptors in the anterior pituitary of ovariectomizedrats[J] . Endocrinology,1986, 119:2484-2489.
[24]	Aoki M D, Aoki A, Maldonado C A.Sexual dimorphism of apoptosis in lactotrophs induced by bromocryptine[J] . Histochem Cell Biol,2001, 116:215-222.
[25]	Lamberts S W, Verleun T, Hofland L, et al.Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells[J] .Clin Endocrinol Metab,1986, 63:1342-1347.
[26]	Molitch M E.Prolactinoma in pregnancy[J] . Best Pract Res Clin Endocrinol Metab,2011, 25:885-896.
[27]	Philippe C,Nicolas,Jovenin, et al.Treatment of pituitary adenomas by fractionated stereotactic radiotherapy:A prospective study of 110 patients[J] . Radiation Oncology Biol,2005, 62(2):333-341.
[28]	Shin M.Gamma knife mdiosurgery for pituitary adenoma[J] .Biomed Pharmacother，2002，56：178-181.
[29]	张静华,李秀英,余小平,等.伽玛刀治疗术后残留垂体腺瘤[J] .立体定向和功能性神经外科杂志,2006,19(4):325-326.
[30]	Pollock B E，Nippoldt T B，Stafford S L, et al.Results of stereotactic radiosurgery in patients with hormone-producing pituitary adenomas：factors associated with endocrine normalization[J] .Natural，2002，97：525-530.